Sun Pharma Advanced Research Company liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

9.06×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
2.47×	2.47×	0.07×	1.02×	2.54×
2.47×	2.47×	0.07×	1.02×	2.54×
1.2	1.2	2.0	7.1	291
1,108	1,108	−348	4.3	276

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health

₹ CrorePeersSTAR SHILPAMED SUPRIYA THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹5,938 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	9.06
Current Ratio	2.54	1.02	0.07	2.47	2.47
Quick Ratio	2.54	1.02	0.07	2.47	2.47
Cash, Equiv & ST Investments	291.5	7.1	2.0	1.2	1.2
Working Capital	276.0	4.3	-348.1	1,108.3	1,108.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.